Cancer Biopsy Market Share, Size, Trends, Industry Analysis Report, By Type (Liquid, Biopsy, Tissue Biopsy, and Others); By Product Type; By Application; By Region; Segment Forecast, 2024- 2032
The global cancer biopsy market size is expected to reach USD 92.09 billion by 2032, according to a new study by Polaris Market Research. The report “Cancer Biopsy Market Share, Size, Trends, Industry Analysis Report, By Type (Liquid, Biopsy, Tissue Biopsy, and Others); By Product Type; By Application; By Region; Segment Forecast, 2024- 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.
A biopsy is a medical procedure that involves extracting tissue from any part of the body to detect diseases. Different methods, including needle-based or surgical extraction, are used. Imaging tests such as MRIs and CT scans can identify abnormalities, but they cannot differentiate between cancerous and non-cancerous cells. Therefore, biopsies are essential to confirm malignancy diagnoses and involve detailed cellular analysis.
Advancements in liquid biopsies have significantly influenced the growth of the cancer biopsy market. This innovative technique analyzes genetic material in the bloodstream, making it possible to detect and monitor specific cancer types in a non-invasive approach.
Biopsies offer crucial insights into the biology of different cancer types. This information is instrumental in identifying potential drug targets and designing clinical trials to evaluate new therapies. Biopsies are also used to monitor treatment response and identify mechanisms of resistance, contributing to the development of more effective drugs and combination therapies.
The cancer biopsy market is facing numerous challenges. Advanced biopsy techniques and molecular profiling technologies are not readily available in areas with limited resources. Additionally, interpreting complex genomic data requires specialized expertise, which highlights the need for ongoing education and training in oncology. Invasive biopsy procedures can cause discomfort to patients, leading to reluctance to undergo the process. Moreover, the cost of biopsy procedures and related technologies can be too high for some individuals and healthcare systems. It is vital to overcome these challenges to ensure equal access to high-quality biopsy services and to maximize their impact on cancer diagnosis and treatment.
Cancer Biopsy Market Report Highlights
The liquid biopsy segment is expected to grow at the highest CAGR during the projected period on account of wide usage
The kits and consumables segment accounted for the largest market share in 2022, which is mainly driven by cost-effectiveness and higher performance.
The breast cancer segment held a significant market revenue share in 2022, mainly due to its high prevalence rate
North America region dominated the market with a majority share in 2022, owing to exponential growth in the technology and advanced healthcare system
The global key market players include Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., Danaher Corporation, F. Hoffmann-La Roche Ltd., Hologic, Inc
Polaris Market Research has segmented the cancer biopsy market report based on type, product type, application, and region:
Cancer Biopsy, Type Outlook (Revenue - USD Billion, 2019 - 2032)
Liquid, Biopsy
Tissue Biopsy
Others
Cancer Biopsy, Product Type Outlook (Revenue - USD Billion, 2019 - 2032)
Kits and Consumables
Instruments
Services
Cancer Biopsy, Application Outlook (Revenue - USD Billion, 2019 - 2032)
Breast Cancer
Cervical Cancer
Lung Cancer
Colorectal Cancer
Others
Cancer Biopsy, Regional Outlook (Revenue - USD Billion, 2019 - 2032)
North America
U.S.
Canada
Europe
Germany
UK
France
Italy
Spain
Russia
Netherlands
Asia Pacific
China
India
Japan
South Korea
Indonesia
Malaysia
Latin America
Argentina
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
Israel
South Africa